SRM/MRM assay for the fatty acid synthase protein
AssigneeExpression Pathology, Inc.
InventorsDavid B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
Life of this patent
Estimating the term…
Loading patent…
AssigneeExpression Pathology, Inc.
InventorsDavid B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
Estimating the term…
Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the FASN protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an FASN peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
A method for measuring the level of the Fatty Acid Synthase (FASN) protein in a human biological sample of formalin-fixed tissue, comprising detecting and/or quantifying the amount of an FASN fragment peptide in a protein digest prepared from said human biological sample using mass spectrometry;
Dependencies are inferred from the claim text.